JOSE L MENDOZA M.D. NPI 1982648036

NPI Details

Jose L Mendoza, M.D. is a hematology and oncology internal medicine in Clinton, MD with 34 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Jose L Mendoza, M.D. NPI is 1982648036. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

8926 WOODYARD RD
SUITE 201
CLINTON, MD
ZIP 20735-220
Phone: (301) 868-7911
Fax: (301) 868-2285

The NPI 1982648036 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Iron level (HCPCS:83540)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron binding capacity (HCPCS:83550)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Uric acid level, blood (HCPCS:84550)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Glutamyltransferase (liver enzyme) level (HCPCS:82977)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Measurement c-reactive protein for detection of infection or inflammation (HCPCS:86140)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Unclassified drugs (HCPCS:J3490)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Blood test, clotting time (HCPCS:85610)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Phosphate level (HCPCS:84100)
• Administration of prolonged chemotherapy into vein (HCPCS:96416)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)

The enumeration date for this NPI number is 6/16/2006 and was last updated on 5/14/2008.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.